ZENCEIVE Trademark

Trademark Overview

On Wednesday, November 6, 2019, a trademark application was filed for ZENCEIVE with the United States Patent and Trademark Office. The USPTO has given the ZENCEIVE trademark a serial number of 88681679. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 8, 2024. This trademark is owned by Bristol-Myers Squibb Company. The ZENCEIVE trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, including T Cell therapy; P...
zenceive

General Information

Serial Number88681679
Word MarkZENCEIVE
Filing DateWednesday, November 6, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 8, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 6, 2021

Trademark Statements

Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, including T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, November 13, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543
Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events

Event DateEvent Description
Saturday, November 9, 2019NEW APPLICATION ENTERED
Wednesday, November 13, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, January 29, 2020ASSIGNED TO EXAMINER
Wednesday, February 5, 2020NON-FINAL ACTION WRITTEN
Wednesday, February 5, 2020NON-FINAL ACTION E-MAILED
Wednesday, February 5, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, August 5, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, August 5, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, August 5, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, September 1, 2020NON-FINAL ACTION WRITTEN
Tuesday, September 1, 2020NON-FINAL ACTION E-MAILED
Tuesday, September 1, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, February 26, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, February 26, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, March 1, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, March 1, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 17, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 6, 2021PUBLISHED FOR OPPOSITION
Tuesday, April 6, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, June 1, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, December 1, 2021SOU EXTENSION 1 FILED
Monday, January 3, 2022ABANDONMENT - NO USE STATEMENT FILED
Monday, January 3, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Wednesday, January 5, 2022TEAS PETITION TO REVIVE RECEIVED
Wednesday, January 5, 2022PETITION TO REVIVE-GRANTED
Wednesday, January 5, 2022SOU EXTENSION RECEIVED WITH TEAS PETITION
Wednesday, January 5, 2022NOTICE OF REVIVAL - E-MAILED
Tuesday, February 8, 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, February 18, 2022SOU EXTENSION 1 GRANTED
Saturday, February 19, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 24, 2022SOU EXTENSION 2 FILED
Tuesday, May 24, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, May 24, 2022SOU EXTENSION 2 GRANTED
Thursday, May 26, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 28, 2022SOU TEAS EXTENSION RECEIVED
Monday, November 28, 2022SOU EXTENSION 3 FILED
Monday, November 28, 2022SOU EXTENSION 3 GRANTED
Wednesday, November 30, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, May 30, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, May 30, 2023SOU EXTENSION 4 FILED
Tuesday, May 30, 2023SOU EXTENSION 4 GRANTED
Thursday, June 1, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, November 21, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, November 21, 2023SOU EXTENSION 5 FILED
Wednesday, November 22, 2023SOU EXTENSION 5 GRANTED
Thursday, November 23, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 8, 2024ABANDONMENT - NO USE STATEMENT FILED
Friday, July 12, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED

Related Keywords

zenceive diseases pharmaceutical human preparations anti disorders system cancer treatment immune